Clinical Trial

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Study acronym: BRAVESST2
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
Protocol Amendment History 1 change
notable Trial sites expanded: 21 -> 24 locations 2026-05-12
Trial Details
NCT Number NCT07129252
Lead Sponsor Crinetics Pharmaceuticals Inc.
Conditions SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Enrollment 150 participants
Start Date 2025-11-26
Primary Completion 2027-08 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-31